{
    "clinical_study": {
        "@rank": "126339", 
        "brief_summary": {
            "textblock": "The Purposes of this Study are to determine:\n\n      The safety of duloxetine and any side effects that might be associated with it.\n\n      Whether duloxetine can help patients with major depression.\n\n      It is possible that information collected during this study will be analyzed by the sponsor\n      in the future to evaluate duloxetine for other possible uses or for other medical or\n      scientific purposes other than those currently proposed.\n\n      Duloxetine might not have any good effects for you."
        }, 
        "brief_title": "Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression", 
        "completion_date": "August 2002", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  You must be at least 18 years old.\n\n          -  You must be diagnosed with major depressive disorder\n\n          -  You must be able to visit the doctor's office once a week to once every 2 weeks for a\n             total of 8 weeks.\n\n        Exclusion Criteria:\n\n          -  You are a woman and are pregnant or breastfeeding.\n\n          -  You have a current or previous major psychiatric disorder other than depression, such\n             as bipolar disorder, schizophrenia, or other psychotic disorder.\n\n          -  You have a history of alcohol or drug dependence or abuse within the past 6 months.\n\n          -  You are allergic to the study drug or you have experienced allergic reactions when\n             taking several medications at once.\n\n          -  You have a serious medical illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "July 31, 2002", 
        "id_info": {
            "nct_id": "NCT00042575", 
            "org_study_id": "6475", 
            "secondary_id": "F1J-US-HMBY"
        }, 
        "intervention": {
            "intervention_name": "Duloxetine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Duloxetine"
        }, 
        "keyword": "Sad, blue, lack of energy, depressed, hopelessness, guilt", 
        "lastchanged_date": "July 18, 2006", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Trumbull", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaithersburg", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belmont", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042575"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2006"
    }, 
    "geocoordinates": {
        "null": "47.61 -122.201"
    }
}